Skip to main content
Premium Trial:

Request an Annual Quote

Doug Fisher, Arnold Oronsky

Doug Fisher has joined Sera Prognostics as chief business officer. The company also has appointed Arnold Oronsky to its board. Fisher has been a partner at venture capital firm InterWest Partners and served on Sera's board starting in late 2011. Sera said that he has resigned as a director in connection to his joining the company's management team. 

Oronsky is a general partner at InterWest and has investment experience in diagnostics and pharmaceutical companies, Sera said. Before joining InterWest, he was vice president of discovery research at Lederle Laboratories, a division of American Cyanamid.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.